摘要
目的 建立使用离子对反相高效液相色谱测定吉西他滨血药浓度的方法。方法 血浆用三氯乙酸沉淀后取上清液直接进样。色谱柱为Symmetry C18(4.6mm×250mm ,5μm) ,流动相为0.52%的磷酸二氢钠溶液(pH2.66)-乙腈(85:15,含0.202%庚烷磺酸钠)。柱温25℃,流速1.0mL·min-1,检测波长273nm。结果 吉西他滨血药浓度在 0.1~100μg·mL-1内的线性关系良好(r=0.9999),血浆中低、中、高3种浓度的方法回收率在97.39%~103.11%之间,日内RSD≤1.94%,日间RSD≤7.34%。结论 本法快速、灵敏、高效,适于吉西他滨的血药浓度监测。
Abstract
OBJECTIVE To establish a ion-pair RP-HPLC method for the determination of gemcitabine in human plasma. METHODS Samples were prepared by protein precipitation. The column was Waters Symmetry C18(4.6mm×250mm,5μm) and the temperature was set at 25℃.The mobile phase was 0.52% phosphate buffer(pH2.66)-acetonitrile(85∶15) containing 0.202% sodium 1-heptanesulfonate and the flow rate was 1.0 mL·min-1.The detection wavelength was at 273 nm.RESULTS The range of calibration curve was 0.1~100μg·mL-1 (r=0.9999).The recovery of low, medium and high concentration were within 97.39%~103.11%.The RSD of intra-run and inter run did not exceed 1.94% and 7.34% respectively.CONCLUSION The method is rapid, sensitive and efficient.
关键词
吉西他滨 /
反相高效液相色谱法 /
离子对
{{custom_keyword}} /
Key words
gemcitabine /
RP-HPLC /
ion-pair
{{custom_keyword}} /
王临润;黄明珠;申屠建中;蔡捷.
离子对反相高效液相色谱法测定人血浆中吉西他滨的药物浓度[J]. 中国药学杂志, 2005, 39(04): 295-296
WNG Lin-run;HUNG Ming-zhu;SHENTU Jin-zhong;CI Jie.
Determination of gemcitabine in human plasma by ion-pair RP-HPLC [J]. Chinese Pharmaceutical Journal, 2005, 39(04): 295-296
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1]傅德良,倪泉兴,虞先浚,等.胰腺区域动脉灌注治疗胰腺癌的实验研究[J].中华医学杂志,2002,82(6):371.
[2]Wang LZ, Goh BC, Lee HS, et al. An expedient assay for determination of gemcitabine and its metabolite in human plasma using isocratic ion-pair reversed-phase high-performance liquid chromatography[J].Therapeutic Drug Monitoring,2003,25:552.
[3]Jody Z, Kerr SL, Berg RD,et al. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates[J].Cancer Chemother Pharmacol,2001, 47:411.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
浙江省医药卫生科学研究基金资助(2004A028)
{{custom_fund}}